Loading…
for educational and safety purposes
Coluracetam and Aniracetam both come up in the same conversations; they overlap on Acetylcholine. Coluracetam: Coluracetam has the most distinctive proposed mechanism in the racetam family. Aniracetam: Aniracetam is a fat-soluble member of the racetam family and one of the original ampakines, a positive allosteric modulator of AMPA-type glutamate receptors used as a cognition enhancer.
Coluracetam has the most distinctive proposed mechanism in the racetam family. Rather than acting at a receptor, it was designed to raise the rate at which neurons take up choline, the raw material the brain uses to build acetylcholine. Mitsubishi developed it in Japan in the 1990s as an Alzheimer's candidate, and it was later carried into depression research and through a completed 115-person trial. Readers who use it describe sharper focus and, unusually for a nootropic, changes in visual vividness. The evidence for the mechanism is narrower than the reputation: the choline-uptake effect was shown in animals whose cholinergic neurons had been deliberately lesioned first and not in normal tissue, and an independent group at Pfizer testing the same transporter across four separate methods found no effect at all. That lesion-dependence is itself worth understanding, because it would predict a quieter effect in a healthy brain rather than none. No human trial has yet reported a cognitive result; the 2009 study completed without publishing its outcomes.
Aniracetam is a fat-soluble member of the racetam family and one of the original ampakines, a positive allosteric modulator of AMPA-type glutamate receptors used as a cognition enhancer. By slowing the desensitization of these excitatory receptors it strengthens the synaptic transmission tied to learning and memory, and it has been used clinically abroad for cognitive symptoms after stroke and in dementia. Its principal metabolite, 2-pyrrolidinone, has been reported to produce a longer-lasting enhancement of AMPA-receptor function through a CaMKII-dependent pathway. It is also noted for anxiolytic and mood effects in animal models.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
mild potentiation
positive modulator
enhances
Increase, again restricted to lesioned tissue. Reversed the AF64A-induced fall in potassium-evoked ACh release from hippocampal synaptosomes and slices, and restored basal hippocampal ACh by in vivo microdialysis. In mice, only chronic dosing restored hippocampal ACh; acute dosing did nothing.
No inhibition. This is affirmative negative evidence from a direct assay, and it distinguishes coluracetam from donepezil, tacrine and the rest of the cholinesterase-inhibitor class.
strengthens
Proposed positive modulator. Reported to raise the Vmax of high-affinity choline uptake about 1.6-fold and the Bmax of [3H]-hemicholinium-3 binding about 1.7-fold, interpreted as driving more transporter to the synaptic membrane rather than changing transporter affinity. Critically, the effect is reported ONLY in cholinergically lesioned tissue and is absent in normal tissue.
No binding. Neither [3H]-quinuclidinyl benzilate (general muscarinic) nor [3H]-pirenzepine (M1-preferring) binding was affected, so the compound is not a muscarinic ligand.
increases
mild agonist
modulates
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Aniracetam is currently listed by more trusted vendors (2), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.